Abstract: An object is to accurately calculate an index indicating a probability of an event occurring to a patient in the future. A mortality risk calculation unit acquires a heart/mediastinum ratio (H/M ratio), obtained by administering a heart function diagnostic medicine to a first subject, from subject data stored in a subject data storage unit, and calculates an index indicating a probability of a predetermined event occurring to the first subject by substituting the H/M ratio acquired from the subject data storage unit into a function defined in accordance with a history of occurrences of the predetermined event to a plurality of second subjects.

Abstract: An object is to more accurately compare diagnosis indexes with each other, which are calculated from data obtained in different environments with a cardiac-function diagnostic medicine. A conversion function calculation unit acquires a first phantom Heart/Mediastinum ratio (H/M ratio) and a second phantom H/M ratio based on a phantom, the first phantom H/M ratio that is an H/M ratio of the phantom in the first imaging environment being acquired by performing, based on phantom data that is data of a first phantom image obtained by imaging the phantom in the first imaging environment and digital phantom data that is data of a digital phantom including a cardiac ROI and a mediastinum ROI, positioning of the digital phantom on the first phantom image, and by calculating based on the phantom data of the first phantom image to which the cardiac ROI and the mediastinum ROI are set; and obtains a conversion function based on the first phantom H/M ratio and the second phantom H/M ratio.

Abstract: An analysis method is provided that ensures objective and quantitative analysis for analyzing time-series images.

Abstract: In order to provide a tomographic image analyzing apparatus which is simple and which obtains stable results, the tomographic image analyzing apparatus according to this invention includes an image standardizing unit which transforms PET images, in advance of tomographic image analysis, so that the contour of the brain of an subject appearing in the PET images become the contour of a brain represented by standard data. By carrying out such transforming operation before the analysis, there is no need to acquire MRI images like before, to be able to ease the burden on the subject. And according to this invention, the time of analysis is shortened. Further, according to this invention, an analysis of time variations of radioactive drug distribution is conducted with respect to a corresponding site on standardized PET images which corresponds to the ROI on the standard data. This can make analysis results stable.

Abstract: The present invention provides a compound represented by the formula (1) or a salt thereof, or a complex of the compound or the salt with a metal, in the formula (1), A1 represents a chelate group; R1 represents a hydrogen atom or the like; R2 represents a hydrogen atom or the like; and Z1, Z2, Z3, Z4, and Z5 are the same or different and each represent a nitrogen atom or CR3 or the like wherein R3 represents a hydrogen atom or an optionally substituted C1-6 alkyl group or the like; L1 represents a group represented by the formula (3) wherein R13, R14, R15, and R16 are the same or different and each represent a hydrogen atom or the like; L2 represents an optionally substituted C1-6 alkylene group; and L3 represents an optionally substituted C1-6 alkylene group.

Abstract: In order to provide a tomographic image analyzing apparatus which is simple and which obtains stable results, the tomographic image analyzing apparatus according to this invention includes an image standardizing unit which transforms PET images, in advance of tomographic image analysis, so that the contour of the brain of an subject appearing in the PET images become the contour of a brain represented by standard data. By carrying out such transforming operation before the analysis, there is no need to acquire MRI images like before, to be able to ease the burden on the subject. And according to this invention, the time of analysis is shortened. Further, according to this invention, an analysis of time variations of radioactive drug distribution is conducted with respect to a corresponding site on standardized PET images which corresponds to the ROI on the standard data. This can make analysis results stable.

Abstract: A radioactive metal-labeled anti-cadherin antibody which is obtained by binding a radioactive metallic element to an anti-cadherin antibody via a metal-chelating reagent.

Abstract: An object of the present invention is to provide a radioactive metal anti-cadherin antibody which is highly accumulated specifically in cancer tissue. Another object is to provide a cancer therapeutic agent having high anti-cancer effect and safety and a cancer diagnostic agent. The radioactive metal-labeled anti-cadherin antibody is obtained by binding a radioactive metallic element to an anti-cadherin antibody via a metal-chelating reagent.

Abstract: Disclosed are: an anti-podoplanin antibody which has a high binding activity and a high effector activity and has low antigenicity in humans or mice; and others. Specifically disclosed are: a chimeric antibody comprising an anti-podoplanin antibody for which an epitope is a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:1 (excluding rat NZ-1 antibody having a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:2 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:3), and a heavy chain complementarity determining region and a light chain complementary determining region of the anti-podoplanin antibody; and others.

Abstract: An object of the present invention is to provide a radioactive metal anti-cadherin antibody which is highly accumulated specifically in cancer tissue. Another object is to provide a cancer therapeutic agent having high anti-cancer effect and safety and a cancer diagnostic agent. The radioactive metal-labeled anti-cadherin antibody is obtained by binding a radioactive metallic element to an anti-cadherin antibody via a metal-chelating reagent.

Abstract: A diagnostic agent for infectious diseases which is capable of distinguishing among different kinds of bacterial species and which allows simple and non-invasive measurement and/or imaging in a short period of time is provided; and a screening method for a therapeutic agent for infectious diseases caused by microorganisms are provided. A diagnostic agent for infectious diseases caused by nitroimidazole susceptible microorganisms, containing an imidazole derivative or a fused imidazole derivative having at least one nitro group on an imidazole ring, or a labeled form thereof as an active ingredient is provided.

Abstract: Disclosed is a radioactive bone diagnostic agent which gives a high ratio of radioactivity accumulation in bone to that in blood from an early stage after administration of the agent and allows capturing an image in a short time after administration. Also disclosed is a bisphosphonic acid derivative represented by the following chemical formula (II) or a salt thereof, wherein X represents —(CH2)mCO—, Y represents —(CH2)n—, R represents H, OH, or a halogen atom, m and n are independent of each other and m represents an integer of 1 to 3, and n represents an integer of 0 to 4.

Abstract: To provide a diagnostic drug which binds specifically to an amyloid aggregate and/or an amyloid deposit, to thereby realize imaging and quantification of a disease caused by amyloid aggregation and/or deposition. The invention provides a compound represented by formula (1): (wherein X1 represents an optionally substituted bicyclic heterocyclic group; X2 represents a hydrogen atom, a halogen atom, or a chelate-forming group; ring A represents a benzene ring or a pyridine ring; and ring B represents an optionally substituted 5-membered aromatic heterocyclic group which is bonded to the benzene ring or the pyridine ring via a carbon atom of ring B), a salt thereof, a solvate of any of these, or a transition metal coordination compound of any of these, and a diagnostic, preventive, or therapeutic drug containing the same.

Abstract: To provide a brain-image diagnosis supporting method or the like. The method is a statistical evaluation method excluding the subjective judgment of an examiner, and enables image diagnosis. The method can present stable judgment criteria with respect to data on brain images imaged by a predetermined method in order to discriminate difficult diseases to diagnose. The method is also effective with respect to relationships which can not be always explained with a simple linear relationship, for example, the relationship between data on brain images imaged by a predetermined method and a disease which is a variable. By applying a predetermined nonlinear multivariate analysis method to data on brain images of a plurality of examinees imaged by a predetermined method and by classifying the data, image diagnosis support using a computer performed with respect to the data on brain images is performed. For example, SOM method is applied as a predetermined nonlinear multivariate analysis method.

Abstract: An object of the present invention is to provide a composition for effectively labeling ECD with 99mTc within a short period of time. The composition for producing [N,N?-ethylenedi-L-cysteinate(3-)]oxotechnetium(99mTc) diethyl ester is characterized by containing N,N?-(1,2-ethylene)bis-L-cysteine diethyl ester or a salt thereof, a reducing agent, and an acidic substance or a salt thereof.

Abstract: Disclosed is a diagnostic agent which is useful for imaging the site of application at which the highest therapeutic effect is expected (i.e., the site where an HGF receptor is expressed) in the therapy of an ischemic disease with an HGF plasmid for the purpose of promoting the angiogenesis with good efficiency. The diagnostic agent is for a disease associated with a hepatocyte growth factor receptor. wherein the drug includes: a labeled product of a partial polypeptide of hepatocyte growth factor containing a heparin-binding domain; or a labeled product of a polypeptide which consisting of an amino acid sequence in which one or several amino acid residues are substituted, deleted or added to the amino acid sequence of the partial polypeptide and having a heparin-binding activity.

Abstract: To provide a diagnostic drug which binds specifically to an amyloid aggregate and/or an amyloid deposit, to thereby realize imaging and quantification of a disease caused by amyloid aggregation and/or deposition. The invention provides a compound represented by formula (1): (wherein X1 represents an optionally substituted bicyclic heterocyclic group; X2 represents a hydrogen atom, a halogen atom, or a chelate-forming group; ring A represents a benzene ring or a pyridine ring; and ring B represents an optionally substituted 5-membered aromatic heterocyclic group which is bonded to the benzene ring or the pyridine ring via a carbon atom of ring B), a salt thereof, a solvate of any of these, or a transition metal coordination compound of any of these, and a diagnostic, preventive, or therapeutic drug containing the same.